Dr Reddy's & FDC Recall Products in US for Manufacturing Issues

By By Rediff Money Desk, New Delhi
Nov 17, 2024 11:25
Dr Reddy's Laboratories and FDC Ltd are recalling generic medications in the US due to manufacturing issues. The recall affects Morphine Sulfate extended-release tablets and Timolol Maleate ophthalmic solution.
New Delhi, Nov 17 (PTI) Dr Reddy's Laboratories and FDC Ltd are recalling generic medications in the US market due to manufacturing issues, according to the US health regulator.

As per the latest Enforcement Report by Food and Drug Administration (USFDA), the US-based subsidiary of Dr Reddy's Laboratories is recalling multiple strengths of Morphine Sulfate extended-release tablets in the US.

The medication is used to relieve severe and persistent pain.

As per the USFDA, Princeton-based Dr Reddy's Laboratories Inc is recalling 2,040 bottles of 15 mg Morphine Sulfate extended-release tablets due to "Failed Impurities/Degradation Specification".

The drugmaker is also recalling another 532 100-count bottles of the medication in 30 mg strength for the same reason, USFDA stated.

Dr Reddy's initiated the Class II nationwide recall on October 22 this year.

USFDA said Mumbai-headquartred FDC Ltd is recalling 1,55,232 bottles of Timolol Maleate ophthalmic solution in the US market.

The company is recalling the affected lot due to "Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle", the US health regulator stated.

The company initiated the Class II recall on October 29, 2024.

Timolol Maleate ophthalmic solution is used to treat high pressure inside the eye due to glaucoma.

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

India is the largest supplier of generic medicines with around 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.

The products manufactured in the country are shipped to over 200 countries around the globe, with Japan, Australia, West Europe, and the US as the main destinations.
Source: PTI
Read More On:
dr reddy'sfdcgeneric medicationsusfdarecallmanufacturing issuesmorphine sulfatetimolol maleateophthalmic solutiondrug recallpharmaceutical industryindiageneric drugsglobal supply
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Tech Transfer Pacts for NaMPET Innovations:...

India's Ministry of Electronics and IT (MeitY) signs technology transfer and...

Sonowal Unveils Shipbuilding Tech at Cochin...

Union Minister Sarbananda Sonowal inaugurated advanced machinery at Cochin Shipyard,...

MMR Growth Hub: Fadnavis Pushes for Speedy...

Maharashtra CM Devendra Fadnavis emphasizes the need for swift implementation of growth...

Refex Renewables Wins Rs 78 Cr Waste Management...

Refex Renewables & Infrastructure has secured a Rs 78 crore order to build a waste...

Tripura CM Chairs Task Force for NE Investment

Tripura CM Manik Saha chairs the first meeting of the high-level task force on...

Coffee Day Enterprises Default: Rs 425.38 Crore...

Coffee Day Enterprises Ltd has reported a total default of Rs 425.38 crore on loans...

Saline Water Aquaculture Boost: Centre Calls...

India's Centre calls for collaboration to boost saline water aquaculture in Haryana,...

IT Stocks Plunge Amid Recession Fears - PTI

Indian IT stocks tumbled on Monday amid recession fears fueled by US tariff hikes,...

Vi Launches 5G in Kolkata, Limited to Eden Gardens

Vodafone Idea (Vi) launches 5G services in Kolkata, initially available only at Eden...

Sensex, Nifty Plunge: Trade War Fears Hit Markets

Indian stock markets suffered their worst single-day decline in 10 months as fears of a...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com